Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-03-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding a change in accounting policies due to new accounting standards issued by the Ministry of Finance of China. It details the reasons for the change, the effective dates, the impact on financial results, and approvals by the board and supervisory committee. The document does not contain full financial statements or comprehensive financial data but rather explains the policy change and its effects. It is not a full annual or interim report, nor is it a certification or a brief announcement of a report publication. Given the content and length (2560 characters), it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting policy changes without full financial statements or detailed financial analysis.
2023-03-29 Chinese
2022年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report". It details the supervisory board's activities, meetings, and oversight of the company's operations, financials, internal controls, and compliance with laws and regulations during the 2022 fiscal year. It includes references to audit reports and financial reports but does not itself contain full financial statements or detailed financial data. The document is a report from the supervisory board summarizing their work and oversight rather than a full annual report or audit report. It is not an announcement or a brief notice but a substantive report on supervisory activities. This fits best under the category of Audit Report / Information (AR), as it relates to oversight, audit opinions, and internal control evaluations, but is not the full annual report (10-K) or interim report (IR). The document length is 3510 characters, which is substantive but not extremely long, consistent with a supervisory board report. FY 2022
2023-03-29 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告全文" which translates to "2022 Annual Report Full Text" for 云南沃森生物技术股份有限公司 (Walvax Biotechnology Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, important matters, shareholder information, bond information, and financial statements. The document includes audited financial data, management's discussion and analysis, and comprehensive disclosures about the company's operations and financial performance for the full fiscal year 2022. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the full annual report, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-03-29 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth meeting of the fifth board of directors of Yunnan Watson Biotechnology Co., Ltd. It includes approvals of the 2022 annual report, audited financial report, management reports, ESG report, profit distribution plan, and other corporate governance matters. The document references that the full reports are available on the designated disclosure website (巨潮资讯网) and that these resolutions will be submitted to the 2022 annual general meeting for approval. The document is not the annual report itself but a board meeting resolution announcement related to the annual report and other governance matters. It is a formal disclosure of board decisions rather than the full report or financial statements. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management decisions.
2023-03-29 Chinese
2022年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 2022 年度财务决算报告' which translates to 'Yunnan Watson Biotechnology Co., Ltd. 2022 Annual Financial Settlement Report'. It contains detailed financial statements including balance sheets, profit and loss statements, cash flow statements, and notes. The document also includes audited financial data for the full fiscal year 2022, with comparisons to the previous year, and explanations of changes in financial positions and results. The presence of comprehensive financial data and analysis for the full fiscal year indicates this is an Annual Report. There is no indication that this is merely an announcement or a certification, and the document length (over 10,000 characters) supports it being a full report rather than a brief announcement. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-03-29 Chinese
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2022 by 云南沃森生物技术股份有限公司. It extensively discusses the company's internal control systems, risk management, compliance, governance, operational processes, and other management aspects. The content is detailed and comprehensive, covering multiple facets of internal control and corporate governance, including organizational structure, strategic planning, social responsibility, R&D, production, quality management, sales, procurement, international business, project management, contract management, and information management. There is no indication that this is an announcement or a brief summary; rather, it is a full report on the internal control self-evaluation. This type of document aligns with the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations, excluding full annual reports. It is not an Annual Report (10-K) as it does not cover full financial performance or company activity broadly, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains substantive content and analysis. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-03-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.